Rajeshwari Sridhara

FDA Drug Approval Summary: Gefitinib (ZD1839) (Iressa®) Tablets

Martin H. Cohen, Grant A. Williams, Rajeshwari Sridhara et al. · The Oncologist · 2003 · 569 citations · Full text

Gefitinib 250, Oncology, Cancer Management +11

United States Food and Drug Administration Drug Approval Summary

Martin H. Cohen, Grant A. Williams, Rajeshwari Sridhara et al. · Clinical Cancer Research · 2004 · 500 citations

Gefitinib Therapy, Drug Policy, Cancer Pharmacology +22

Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement

Edward S. Kim, Suanna S. Bruinooge, Samantha Roberts et al. · Journal of Clinical Oncology · 2017 · 448 citations

Eligibility Criteria, Clinical Endpoint, American Society +16

FDA Drug Approval Summary: Erlotinib (Tarceva®) Tablets

Martin H. Cohen, John R. Johnson, Yeh‐Fong Chen et al. · The Oncologist · 2005 · 434 citations

United States Food and Drug Administration Approval Summary: Bortezomib for the Treatment of Progressive Multiple Myeloma after One Prior Therapy

Robert C. Kane, Ann T. Farrell, Rajeshwari Sridhara et al. · Clinical Cancer Research · 2006 · 344 citations · Full text